
Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada
Dexcom, Inc. (NASDAQ: DXCM), a market leader in real-time continuous glucose monitoring (rtCGM) for individuals with diabetes, has announced the launch of its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System in Canada beginning October 10, 2023. There are approximately 4 million people in Canada with type 1 and type2 diabetes who have been diagnosed.
Dexcom G7 was engineered with a focus on comfort and simplicity. It boasts several key features that set it apart from its predecessor devices including the fact that the Dexcom G7 sensor is the smallest ever created, designed for comfort and discretion. The sensor’s one-push applicator with an all-in-one sensor is painless and requires no assembly. 96% of device users found this sensor easy to use, and the sensor only requires 30 min. to warm-up and provide readings. No finger sticks are required for device calibration either. The device also provides customizable alerts including predictive alerts that notify diabetics in advance of severe hypoglycemia allowing proactive intervention. Patients can also share their data with up to 10 individuals such as parents and physicians. The device is also waterproof and can be suspended under up to eight feet of water for 24 hours.
The Dexcom G7 has also displayed high accuracy in clinical studies with a mean absolute relative difference (MARD) of 8.2% for adults and 8.1% for pediatric patients. This measures the average difference between device readings and actual blood glucose measurements. This number is the best among major commercially marketed continuous glucose monitors.
The FDA approved the G7 in December 2022 and Dexcom initiated the full U.S. launch in Feb. 2023. The device received CE Mark in March 2022 and was launched in multiple additional countries in 2022.
André Côté, Vice President and General Manager of Dexcom Canada, stated, “CGM has become the standard of care for diabetes management for good reason. We strongly believe that Canadians who are now able to access Dexcom G7 CGM will immediately benefit from the improved accuracy and easy-to-adopt user experience, while finding comfort in the trusted technology that Dexcom has pioneered. Our top priority will always be to empower those living with diabetes to make more insightful decisions about food, activity, and treatment in a simple and effective way, and Dexcom G7 allows us to achieve that with more impact than ever before.”